Tevogen files for additional patent on predictive AI

Tevogen (TVGN) Bio filed for an additional patent, “Systems And Methods For Predicting Immunologically Active Peptides With Machine Learning Models”, as part of its developing intellectual property portfolio. “When combining our expertise across biopharma and artificial intelligence, we anticipate becoming a leader in the field with breakthroughs to follow,” said Tevogen Bio CEO Dr. Ryan Saadi, M.D., M.P.H. “We will provide additional updates about the company, including our AI effort, at the J.P. Morgan Healthcare Conference in January 2025.”